20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.11M | -3.70M | -3.64M | -4.69M | -5.10M |
| Total Depreciation and Amortization | 81.40K | 87.00K | 99.50K | 113.30K | 126.50K |
| Total Amortization of Deferred Charges | 355.50K | 115.10K | 17.20K | 0.00 | 2.50K |
| Total Other Non-Cash Items | 1.35M | 781.40K | 1.05M | 1.82M | 2.00M |
| Change in Net Operating Assets | 626.40K | 820.30K | 552.00K | 639.90K | 621.50K |
| Cash from Operations | -2.70M | -1.90M | -1.92M | -2.12M | -2.35M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.40K | -- | -- | -- | -- |
| Cash from Investing | -5.40K | -- | -- | -- | -- |
| Total Debt Issued | 1.20M | 1.02M | 611.60K | 105.00K | 70.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.80K | 4.80K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 5.10M | 288.50K | 398.50K | 478.20K | 433.80K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -786.50K | -23.90K | -- | -- | -- |
| Cash from Financing | 5.52M | 1.29M | 1.01M | 583.20K | 503.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.82M | -604.00K | -911.50K | -1.54M | -1.84M |